Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

British Journal of Pharmacology

Volumn 163, Issue 1, 2011, Pages 53-67

  Rabe, Klaus F ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Anti inflammatory; chronic obstructive pulmonary disease; phosphodiesterase 4 inhibitor; roflumilast

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BLEOMYCIN; BUDESONIDE; CILOMILAST; CIMETIDINE; CORTISONE ACETATE PLUS NEOMYCIN; DIGOXIN; ELB 353; ENOXACIN; ERYTHROMYCIN; FORMOTEROL; GSK 256066; IBUDILAST; KETOCONAZOLE; MIDAZOLAM; MONTELUKAST; MUSCARINIC RECEPTOR BLOCKING AGENT; OGLEMILAST; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; RIFAMPICIN; ROFLUMILAST; ROLIPRAM; SALBUTAMOL; SCH 900182; TETOMILAST; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEART DISEASE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INSOMNIA; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG INFILTRATE; MENTAL DISEASE; METABOLIC DISORDER; MORNING DOSAGE; NAUSEA; NEOPLASM; NEUTROPHILIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISEASE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOMITING; WEIGHT REDUCTION;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79953700575     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01218.x     Document Type: Review

References (99)

1. Amschler H, (1995). Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. PCT Patent WO95/01338.
2. Astrup A, Rossner S, Van GL, Rissanen A, Niskanen L, Al HM, et al,. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606-1616.
3. Barnette MS, Underwood DC, (2000). New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 6: 164-169.
4. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, et al,. (2004). Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76: 618-627. (Pubitemid 39601551)
5. Bethke TD, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Hauschke D, et al,. (2006). Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Int J Clin Pharmacol Ther 44: 572-579. (Pubitemid 44718193)
6. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Morike K, et al,. (2007). Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47: 26-36. (Pubitemid 44973995)
7. Böhmer GM, Nassr N, Wenger M, Hunnemeyer A, Lahu G, Templin S, et al,. (2009). The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. J Clin Pharmacol 49: 389-397.
8. Böhmer GM, Gleiter CH, Morike K, Nassr N, Walz A, et al,. (2010). No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using Cimetidine. J Clin Pharmacol DOI: 10.1177/0091270010768282 [Epub ahead of print].
9. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, et al,. (2007). Insulin resistance and inflammation-A further systemic complication of COPD. COPD 4: 121-126. (Pubitemid 47164861)
10. Boswell-Smith V, Spina D, (2007). PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2: 121-129. (Pubitemid 47207736)
11. Boswell-Smith V, Cazzola M, Page CP, (2006a). Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 117: 1237-1243. (Pubitemid 43795733)
12. Boswell-Smith V, Spina D, Page CP, (2006b). Phosphodiesterase inhibitors. Br J Pharmacol 147 (Suppl. 1): S252-S257. (Pubitemid 43077283)
13. Burnouf C, Pruniaux MP, (2002). Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8: 1255-1296. (Pubitemid 34594253)
14. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM, (2007). Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 154-161. (Pubitemid 47057851)
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, (2009). Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694.
16. Calverley PMA, Fabbri LM, Rabe KF, Mosberg H, (2010a). Roflumilast in the treatment of COPD: a pooled safety analysis. Eur Respir J Suppl 36 (Suppl. 54): Abstract P4001.
17. Calverley PMA, Fabbri LM, Rabe KF, Mosberg H, (2010b). Roflumilast in the treatment of COPD: a pooled safety analysis. Presented at the European Respiratory Society Annual Congress, Barcelona, Spain 18-22 September, 2010: Poster 4732.
18. Carnini C, Caruso P, Bassani F, Pisano AR, Riccardi B, Gallo PM, et al,. (2009). Cigarette smoke-induced inflammatory and oxidative response in mice and pharmacological intervention studies involving compounds with different mechanism of action. Am J Respir Crit Care Med 179: A2025.
19. Chapman KR, Rabe KF, (2010). Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol. Prim Care Respir J 19: A12.
20. Chapman RW, House A, Richard J, Fernandez X, Jones H, Prelusky D, et al,. (2010). Pharmacology Of SCH900182, A Potent, Selective Inhibitor Of PDE4 For Inhaled Administration. Am J Respir Crit Care Med 181: A5671.
21. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C, (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278: 5493-5496. (Pubitemid 36800786)
22. Cortijo J, Iranzo A, Milara X, Mata M, Cerda-Nicolas M, Ruiz-Sauri A, et al,. (2009). Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 156: 534-544.
23. Cotreau MM, von Moltke LL, Greenblatt DJ, (2005). The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44: 33-60. (Pubitemid 40100551)
24. David M, Zech K, Seiberling M, Weimar C, Bethke TD, (2004). Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high oral bioavailability. J Allergy Clin Immunol 113: S220-S221.
25. Drollmann A, Hartmann M, Zech K, David M, Weimar C, Bethke T, (2002). Patients with severe renal impairment do not require dose adjustments of roflumilast. Eur Respir J 20 (Suppl. 38): 108s. (Abstract P743).
26. Erdogan S, Houslay MD, (1997). Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 321 (Pt 1): 165-175.
27. Etsuko T, Tamaoki J, Arai N, Kondo M, Nagai A, (2010). Treatment of airway mucus hypersecretion and postnasal drip syndrome by the PDF4 inhibitor ibudilast in patients with chronic airway inflamation. Am J Respir Crit Care Med 181: A5620.
28. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al,. (2009). Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695-703.
29. Field SK, (2008). Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. Expert Opin Investig Drugs 17: 811-818. (Pubitemid 351843624)
30. Fitzgerald MF, (2001). Efficacy of the PDE4 inhibitor, Bay 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig. Am J Respir Crit Care Med 163: A905.
31. Fitzgerald MF, Spicer D, McAulay AE, Wollin L, Beume R, (2006). Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs. Eur Respir J 28 (Suppl. 50): 663s.
32. Food and Drug Administration (2010). Daxas (roflumilast) tablets NDA 22-522. Available at:. (last accessed 19 October 2010).
33. Funck-Brentano C, Raphael M, Lafontaine M, Arnould JP, Verstuyft C, Lebot M, et al,. (2006). Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. Lung Cancer 54: 11-18.
34. Furuie H, Nakagawa S, Kawashima M, Murakami M, Irie S, (2003). Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects. Presented at the 13th Annual European Respiratory Society's Annual Congress, Vienna, Austria. September 27: Abstract 2557.
35. Giembycz MA, (1992). Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 43: 2041-2051.
36. Giembycz MA, (2005). Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 326-333. (Pubitemid 41566944)
37. Giembycz MA, (2006). An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 62: 138-152. (Pubitemid 44316425)
38. Giembycz MA, (2008). Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155: 288-290.
39. Global Initiative for Chronic Obstructive Lung Disease (2009). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2009). National Heart, Lung and Blood Institute: Bethesda, MD.
40. Grootendorst DC, Gauw SA, Benschop N, Sterk PJ, Hiemstra PS, Rabe KF, (2003). Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 16: 341-347. (Pubitemid 37315858)
41. Halpin DM, (2008). ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis 3: 543-561.
42. Hardaker EL, Freeman MS, Dale N, Raza F, Mok J, Banner KH, et al,. (2009). Characterisation of a model that mimicks aspects of the hyper-inflammatory response observed during an acute exacerbation of COPD. Am J Respir Crit Care Med 179: A5351.
43. Hardaker EL, Freeman MS, Dale N, Bahra P, Raza F, Banner KH, et al,. (2010). Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung. Br J Pharmacol 160: 1985-1996.
44. Hatzelmann A, Schudt C, (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279. (Pubitemid 32242587)
45. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al,. (2010). The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-256.
46. Hauns B, Hermann R, Hunnemeyer A, Herzog R, Hauschke D, Zech K, et al,. (2006). Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol 46: 1146-1153. (Pubitemid 44387414)
47. Hermann R, Lahu G, Hauns B, Bethke T, Zech K, (2006). 'Total PDE4 inhibitory activity': a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions. Eur Respir J 28: 436s.
48. Hermann R, Nassr N, Lahu G, Peterfai E, Knoerzer D, Herzog R, et al,. (2007a). Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 46: 403-416. (Pubitemid 46686466)
49. Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B, et al,. (2007b). The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol 47: 1005-1013. (Pubitemid 47094090)
50. Holst JJ, (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439. (Pubitemid 350041474)
51. Jin SL, Bushnik T, Lan L, Conti M, (1998). Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. J Biol Chem 273: 19672-19678. (Pubitemid 28367024)
52. Jin SL, Conti M, (2002). Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99: 7628-7633. (Pubitemid 34568742)
53. Keshavarzian A, Mutlu E, Guzman JP, Forsyth C, Banan A, (2007). Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs 16: 1489-1506. (Pubitemid 47491417)
54. Knowles RG, Ball DI, Gascoigne MH, (2009). In vivo characterisation of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration. Am J Respir Crit Care Med 179: A4582.
55. Lahu G, Hünnemeyer A, von Richter O, Hermann R, Herzog R, McCracken N, et al,. (2008). Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol 48: 1339-1349.
56. Lahu G, Hünnemeyer A, Herzog R, McCracken N, Hermann R, Elmlinger M, et al,. (2009). Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 47: 236-245.
57. Lahu G, Goehring UM, Hunnemeyer A, Nassr N, (2010a). Roflumilast in coadministration with medications commonly prescribed for COPD: an overview of existing studies. Eur Respir J 36 (Suppl. 54): Abstract P4593.
58. Lahu G, Nassr N, Herzog R, Elmlinger M, Ruth P, Hinder M, et al,. (2010b). Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-Oxide. J Clin Pharmacol DOI: 10.1177/ 0091270010370590 [Epub ahead of print].
59. Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, et al,. (2010c). Population pharmacokinetic modelling of roflumilast and roflumilast N-Oxide by total phosphodiesterase 4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49: 589-606.
60. Larson JL, Pino MV, Geiger LE, Simeone CR, (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78: 44-49. (Pubitemid 26041538)
61. Le Quement C, Guenon I, Gillon JY, Valenca S, Cayron-Elizondo V, Lagente V, et al,. (2008). The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 154: 1206-1215. (Pubitemid 351992055)
62. Lipworth BJ, (2005). Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365: 167-175. (Pubitemid 40091808)
63. Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS, et al,. (2004). The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol 32: 295-308. (Pubitemid 38692000)
64. Mangoni AA, Jackson SH, (2004). Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57: 6-14. (Pubitemid 38067945)
65. Martinez FJ, Rabe KF, Wouters EFM, Brose M, Goehring UM, Fabbri LM, et al,. (2010). Time course and reversibility of weight decrease with roflumilast, a phosphodiesterase 4 inhibitor. Am J Respir Crit Care Med 181: A4441.
66. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G, (2005). Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172: 848-853. (Pubitemid 41369068)
67. Martorana PA, Lunghi B, Lucattelli M, De CG, Beume R, Lungarella G, (2008). Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 8: 17.
68. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M, (2003). PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17: 1831-1841. (Pubitemid 37214777)
69. Muller T, Engels P, Fozard JR, (1996). Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci 17: 294-298. (Pubitemid 26261894)
70. Nassr N, Lahu G, Hünnemeyer A, von Richter O, Knoerzer D, Reutter F, et al,. (2007a). Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. J Clin Pharmacol 47: 660-666. (Pubitemid 46632147)
71. Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, et al,. (2007b). Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects. Br J Clin Pharmacol 63: 365-370.
72. Nassr N, Huennemeyer A, Herzog R, von RO, Hermann R, Koch M, et al,. (2009). Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 68: 580-587.
73. Nauck M, Stockmann F, Ebert R, Creutzfeldt W, (1986). Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52. (Pubitemid 16162741)
74. Nycomed GmbH (2009). Data on file. Safety evaluation of roflumilast-mesenteric vasculitis. Nycomed GmbH (previously Altana Pharma AG) 358/2008.
75. Nycomed GmbH (2010a). Data on file, Nycomed GmbH (previously Altana Pharma AG) 134/2006.
76. Nycomed GmbH (2010b). Data on file, Nycomed GmbH (previously Byk Gulden Lomberg Chemische Fabrik GmbH) 213/2000.
77. O'Mahony S, (2005). Tetomilast. Idrugs 8: 502-507.
78. Omar B, Zmuda-Trzebiatowska E, Manganiello V, Goransson O, Degerman E, (2009). Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal 21: 760-766.
79. Ong WK, Gribble FM, Reimann F, Lynch MJ, Houslay MD, Baillie GS, et al,. (2009). The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol 157: 633-644.
80. Pages L, Gavalda A, Lehner MD, (2009). PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Pat 19: 1501-1519.
81. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C, (2007). Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 178: 4820-4831. (Pubitemid 46595264)
82. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD, (2005). Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366: 563-571. (Pubitemid 41140331)
83. Rennard SI, Knobil K, Rabe KF, Morris A, Schachter N, Locantore N, et al,. (2008). The efficacy and safety of cilomilast in COPD. Drugs 68 (Suppl. 2): 3-57.
84. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ, (2011). Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 12: 18 DOI: 10.1186/1465-9921-12-18 [Epub ahead of print].
85. von Richter O, Lahu G, Hünnemeyer A, Herzog R, Zech K, Hermann R, (2007). Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet 46: 613-622. (Pubitemid 47025361)
86. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, et al,. (2002). Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110: 1045-1052.
87. Sanz MJ, Cortijo J, Morcillo EJ, (2005). PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 106: 269-297. (Pubitemid 40726291)
88. Schneider C, Jick SS, Bothner U, Meier CR, (2010). Cancer risk in patients with chronic obstructive pulmonary disease. Pragmatic and Observational Research 1: 15-23.
89. Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, et al,. (2007). A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132: 76-86. (Pubitemid 46108758)
90. Souness JE, Aldous D, Sargent C, (2000). Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47: 127-162. (Pubitemid 30394536)
91. Spina D, (2003). Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63: 2575-2594. (Pubitemid 37491561)
92. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, et al,. (1996). Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 51: 267-271. (Pubitemid 26086470)
93. Stevenson CS, Wan WYH, Mok J, Pearce W, Morris A, Kinnear G, (2009). Does the impact of anti-inflammatory compounds in acute smoking mouse models predict therapeutic efficacy in more chronic models. Am J Respir Crit Care Med 179: A2224.
94. Torphy TJ, Undem BJ, (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46: 512-523.
95. Vakkalanka SKVS, Balasubramaniam G, Gharat LA, Joshi VD, Hussain N, Rao J, (2004). The pharmacological and safety profile of a novel selective phosphodiesterase-4(PDE4) inhibitor:- GRC- 3886. Eur Respir J 24: 220s.
96. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM, (1999). Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56: 170-174. (Pubitemid 29309826)
97. Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D, (2008). Therapeutic effects of various PDE4 inhibitors on cigarette smoke-induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med 178: A651.
98. Wouters EF, Teichmann P, Brose M, Fabbri L, Rabe K, (2010a). Effect of roflumilast on glucose levels in patients with COPD and diabetes mellitus type 2. Presented at the European Respiratory Society Annual Congress, Barcelona, Spain 18-22 September, 2010: Poster 4002.
99. Wouters EFM, Teichmann P, Brose M, Rabe KF, Fabbri LM, (2010b). Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181: A4473.